home / stock / avte / avte news


AVTE News and Press, Aerovate Therapeutics Inc. From 06/09/24

Stock Information

Company Name: Aerovate Therapeutics Inc.
Stock Symbol: AVTE
Market: NASDAQ
Website: aerovatetx.com

Menu

AVTE AVTE Quote AVTE Short AVTE News AVTE Articles AVTE Message Board
Get AVTE Alerts

News, Short Squeeze, Breakout and More Instantly...

AVTE - Where are the Opportunities in (AVTE)

2024-06-09 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

AVTE - Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo

2024-06-07 15:09:58 ET More on Alnylam, Pliant, etc. Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation ...

AVTE - Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM, Mass., May 21, 2024 ...

AVTE - Aerovate Therapeutics reports Q1 GAAP EPS of -$0.83

2024-05-14 12:34:24 ET More on Aerovate Therapeutics Seeking Alpha’s Quant Rating on Aerovate Therapeutics Historical earnings data for Aerovate Therapeutics Financial information for Aerovate Therapeutics Read the full article on Seeking Alpha ...

AVTE - Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Enrollment continues into the Phase 3 portion of the IMPAHCT trial of AV-101 Poster to be presented with baseline char...

AVTE - Trend Tracker for (AVTE)

2024-04-19 19:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

AVTE - Wells Fargo's high-conviction tactical longs and shorts for Q2

2024-04-01 08:53:49 ET More on the markets My Current View Of The Market: April 2024 Edition (Technical Analysis) SPY: Potential, Yes, But Risks Ahead Too Where This Market Is Going (Technical Analysis) Investors are sellers of fund assets for the second cons...

AVTE - (AVTE) Proactive Strategies

2024-03-30 22:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

AVTE - Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 A...

AVTE - Aerovate Therapeutics reports FY results

2024-03-25 17:59:24 ET More on Aerovate Therapeutics Seeking Alpha’s Quant Rating on Aerovate Therapeutics Historical earnings data for Aerovate Therapeutics Financial information for Aerovate Therapeutics Read the full article on Seeking Alpha ...

Previous 10 Next 10